CIP2A在高危局限性前列腺癌中的表达及临床意义  

The expression and clinical significance of CIP2A in high risk localized prostate cancer

作　　者：潘悦[1] 郑克文[1] 陈伟[1] PAN Yue;ZHENG Kewen;CHEN Wei(Department of Urology,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,China)

机构地区：[1]温州医科大学附属第一医院泌尿外科,浙江温州325000

出　　处：《中国现代医生》2020年第2期49-51,I0002,共4页China Modern Doctor

基　　金：浙江省医药卫生科技计划项目(2019KY456);浙江省温州市科技计划经费自筹项目(Y20170441)。

摘　　要：目的探讨蛋白磷酸酶2A的抑制性癌因子(cancerous inhibitor of proteinphosphatase 2A,CIP2A)在高危局限性前列腺癌组织中的表达情况及临床意义。方法选取2010年1月~2016年1月于温州医科大学附属第一医院行手术治疗的50例高危局限性前列腺癌患者为实验组,并选取同期在我院手术治疗的良性前列腺增生患者50例为对照组,应用免疫印迹(western blot)的方法对两组术后标本的CIP2A表达情况进行对比分析,并进一步比较两组CIP2A的表达与临床病理因素的关系。结果实验组中CIP2A的表达明显高于对照组(P<0.05);并且CIP2A的表达与术后1年肿瘤转移复发、Gleason评分、前列腺特异抗原(prostate specific antigen,PSA)水平密切相关(P<0.05)。结论CIP2A在高危局限性前列腺癌中高度表达,有望成为高危局限性前列腺癌早期诊断、术后预测复发转移的一个重要的生物学指标。Objective To explore the expression and clinical significance of cancerous inhibitor of protein phosphatase 2A(CIP2A)in high risk localized prostate cancer.Methods 50 patients with high risk localized prostate cancer who were operated in the First Affiliated Hospital of Wenzhou Medical University from January 2010 to January 2016 were selected as the study group,while 50 patients with benign prostatic hyperplasia who were operated in our hospital at the same period were selected as the control group.The expression of CIP2A after surgery in the two groups was compared by Western blot,and the relationship between CIP2A expression and clinicopathologic factors was analyzed.Results The expression of CIP2A in the study group was significantly higher than the control group(P<0.05),and the expression of CIP2A was closely related to tumor metastasis and recurrence,Gleason score,prostate specific antigen(PSA)level in one year after operation(P<0.05).Conclusion The high expression of CIP2A in high risk localized prostate cancer is expected to be an important biological index for early diagnosis and postoperative prediction of recurrence and metastasis of high risk localized prostate cancer.

关 键 词：高危局限性前列腺癌 CIP2A GLEASON评分 PSA 

分 类 号：R737.2[医药卫生—肿瘤]